KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Beginning Cash Balance: 2018-2025

Historic Beginning Cash Balance for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to $86.1 million.

  • Esperion Therapeutics' Beginning Cash Balance fell 54.54% to $86.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $144.7 million, marking a year-over-year increase of 26.02%. This contributed to the annual value of $82.2 million for FY2024, which is 34.08% down from last year.
  • Per Esperion Therapeutics' latest filing, its Beginning Cash Balance stood at $86.1 million for Q3 2025, which was down 24.92% from $114.6 million recorded in Q2 2025.
  • Over the past 5 years, Esperion Therapeutics' Beginning Cash Balance peaked at $305.0 million during Q1 2021, and registered a low of $82.2 million during Q1 2024.
  • Moreover, its 3-year median value for Beginning Cash Balance was $138.5 million (2023), whereas its average is $137.4 million.
  • As far as peak fluctuations go, Esperion Therapeutics' Beginning Cash Balance soared by 101.98% in 2022, and later slumped by 54.54% in 2025.
  • Over the past 5 years, Esperion Therapeutics' Beginning Cash Balance (Quarterly) stood at $103.7 million in 2021, then spiked by 101.98% to $209.4 million in 2022, then crashed by 45.16% to $114.8 million in 2023, then climbed by 26.02% to $144.7 million in 2024, then crashed by 54.54% to $86.1 million in 2025.
  • Its last three reported values are $86.1 million in Q3 2025, $114.6 million for Q2 2025, and $144.8 million during Q1 2025.